Research programme: clofarabine - Heidelberg Pharma Research

Drug Profile

Research programme: clofarabine - Heidelberg Pharma Research

Alternative Names: Clofarabine-EPD; EPD-clofarabine; HDP 15.0022

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heidelberg Pharma
  • Developer Heidelberg Pharma Research
  • Class Antineoplastics; Furans; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 09 Oct 2017 Heidelberg Pharma is now called Heidelberg Pharma Research
  • 28 Feb 2011 Heidelberg Pharma has been acquired by Wilex
  • 15 Nov 2010 Suspended - Preclinical for Solid tumours in Germany (PO) before November 2010
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top